Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine ..."
 
Vol 7, No 2 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
"... context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... -effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... to radioactive iodine in patients – residents of the Russian Federation. Materials and Methods. The budget ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat ..."
 
Vol 5, No 1 (2012) DYNAMICS OF PREFERENTIAL MAINTENANCE OF CITIZENS WITH ANTIHYPERTENSIVE DRUGS AT THE EXPENSE OF THE REGIONAL BUDGET Abstract  similar documents
I. I. Lavrentyeva, A. I. Khokhlov, I. N. Kagramanyan, T. A. Gorokhova
"...  on medicinal maintenance lays down on the regional budget. The analysis of dynamics of maintenance sick ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... the federal healthcare budget. Materials and Methods. Based on the results of the DURABLE clinical trial, we ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... позволит в рамках текущего бюджета системы здравоохранения дополнительно пролечить 34 больных данной ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... , for the account of healthcare and social security budget of the constituent members of the Russian Federation; 2 ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... бюджета, обусловленной различиями в стоимости ЛП, в течение трех лет в размере 26,4 млн руб. (0,62%) при ..."
 
Vol 10, No 2 (2017) COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Abstract  similar documents
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
"... . Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis ..."
 
Vol 10, No 4 (2017) SOURCES OF BIAS IN SELF-ASSESSED HEALTH Abstract  similar documents
C. J. Gerry, V. M. Baydin
"... and quality of life of the population. However, SAH is a subjective indicator and subject to bias stemming ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpik
"... by mean of costefficacy and budget impact analysis. Results have shown, that Azopt has benefits compare ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..."
 
Vol 8, No 3 (2015) GOVERNMENTAL FUNDING OF BIOMEDICAL RESEARCH IN THE UNITED STATES OF AMERICA, GREAT BRITAIN AND GERMANY Abstract  similar documents
G. R. Khachatrtyan, O. Yu. Rebrova, V. V. Omelyanovskiy
"... of the governmental budget in biomedical research and about focus themes within biomedical research founded in open ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... to perform the cost-effectiveness analysis,  incremental analysis, and «budget impact» analysis. Results ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... optimization in the Republic of Tatarstan. Materials and methods. A budget impact model was created to compare ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization ..."
 
Vol 10, No 1 (2017) PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS Abstract  similar documents
A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina
"... . Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used. Results ..."
 
Vol 5, No 2 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpikov
"... analogues and beta-blockers by mean of cost-efficacy and budget impact analysis. Results have shown ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2 ..."
 
Vol 13, No 2 (2020) Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation Abstract  similar documents
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... and budget impact analyses were performed. Results. The drug costs for T+O were the lowest among all ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... minimization and budget impact analysis was conducted. Results have shown, that Azarga has benefits compare ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... , the results of budget impact analysis illustrate that including сerebrolysin into the standard therapy ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... research compared the cost-effectiveness and the budget impact results of using Contour TS, Accu-Chek ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... therapy, the total budget savings can reach more than 327 million rubles. Conclusion. The use ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
"... / umeclidinum bromide and olodaterol / tiotropium bromide, and evaluate the ways of minimizing health budget ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA Abstract  similar documents
M. Yu. Frolov, O. V. Shatalova
"... – effectiveness analysis, budget impact analysis (in relation to the State Guarantees Program) as well ..."
 
Vol 10, No 4 (2017) IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET Abstract  similar documents
V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva
"... of the national budget. In this article, we propose a novel concept of price control relevant to Russia, which ..."
 
Vol 11, No 4 (2018) Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense Abstract  similar documents
D. V. Lukyantseva, L. S. Melnikova, D. V. Fedyaev, T. P. Bezdenezhnykh, V. V. Omelyanovskiy
 
Vol 8, No 3 (2015) ORGANIZATION AND ANALYSIS OF THE COMMISSION'S WORK ON THE SELECTION AND REFERRAL OF PATIENTS IN A MEDICAL INSTITUTION FOR TREATMENT USING ASSISTED REPRODUCTIVE TECHNOLOGIES ON THE TERRITORY OF THE CHELYABINSK REGION Abstract  similar documents
M. G. Moskvicheva, V. V. Saharova, Yu. A. Semenov, E. V. Orehova
"... at the expense of means of regional and federal budgets. In the work the Commission considers indications ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... and efficiency were taken from D. Cibrik et al. (2013) randomized control trial. We also estimated the budget ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... was calculated based on the shadow budget price (i. e. determining the WTPT by the suppling party). This method ..."
 
Vol 10, No 1 (2017) THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva
"... better decision-making on financing the medical treatment within a limited budget. With this algorithm ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"... country. A limited budget for treatment of such patients determines significant difficulties for its ..."
 
Vol 12, No 2 (2019) Health technology assessment and reimbursement of pharmaceuticals in Italy Abstract  similar documents
F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan
"... technologies is taken into consideration for decision-making, in practice, the main focus rests on the budget ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... reduces total costs of treatment and nursing of these patients with minimum effect on the budget. ..."
 
Vol 13, No 2 (2020) Prognosis of the influence of direct oral anticoagulants on the direct medical expenses in patients with atrial fibrillation Abstract  similar documents
S. V. Malchikova, A. N. Korobeinikova, N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva
"... ”, “budget impact”, and “the analysis of unseized opportunities”. Results. Total direct costs (DC) were ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia Abstract  similar documents
I. A. Metelkin, R. I. Yagudina
"... : Pharmacoeconomic analysis: «budget impact analysis» and «lost opportunities analysis» was provided. Only direct ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... from federal and regional budgets in 2013 in the regions of the Russian Federation for patients ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"... combination in comparison to adalimumab and infliximab showed the positive budget impact. Conclusion ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... with increasing expenses and thus impacts the healthcare budgets at various levels. The aim was to study ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... and budget impact analysis. Results. We found that approx. 250,000 patients in Russia need combined ..."
 
1 - 50 of 72 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)